The Food and Drug Administration announced Wednesday that it has approved a new drug called Dafluvix, a new blood test that will be available to people with type 1 diabetes.
The test can be used to check for the presence of diabetes-causing enzymes in blood, the FDA said in a news release.
It’s been tested in people with Type 1 diabetes for at least six years and is currently used in clinical trials.
The drug has been approved by the FDA for use in people who have Type 1 and 2 diabetes.
People with Type 2 diabetes are people with the disease whose immune systems do not respond well to insulin.
Dafluvenix was developed by a group of scientists from the University of Washington and Harvard Medical School and is the result of a collaboration between the researchers and a biotech company called AbbVie.
The FDA says it is working with Abbvie to ensure the drug is safe and effective for people with diabetes.
Daphne Koller-Hughes, an associate professor of medicine at the University at Albany School of Medicine and director of the Division of Clinical and Translational Sciences, said the drug will help people with this disease, which affects 1 in 8 Americans, but also may be useful for people without diabetes.
Koller-Huguets, who was not involved in the study, said she is not surprised by the approval.
“I think it is a really exciting day,” she said.
“I don’t think we can expect a lot of success from this type of test.”
Koller Hugson said she was impressed with the FDA approval.
The approval comes at a time when diabetes is on the rise in the United States.
A recent study found that a third of the nation’s diabetes cases are attributable to people taking medications with the new blood glucose testing.
The new test will not be available in all states, but it’s expected to be widely available in the next year or so, according to the FDA.
Daffluvax is a modified version of a drug that was approved by European regulators in January.
It can be administered in a pinch and does not require the use of insulin, but there is no way to predict how long it will be effective in people without Type 1 or Type 2.
The new test can detect the presence and level of some of the enzyme enzymes that trigger Type 1, but not Type 2, diabetes.
About 25 million Americans have Type 2 and about 4 million have Type 3 diabetes.
More than 1 million people in the U.S. have diabetes and about half of the population has Type 1.
“This is really important because we’re looking at an increase in the number of people with potentially very severe Type 1- and Type 2-like complications,” Koller Hughes said.
Dalfluvazos is currently undergoing clinical trials in people in their 20s and 30s.
Koller says the drug’s long-term safety should be good and it is being tested in more than 2,500 people in clinical studies.